Design, Synthesis, and In Vitro Biological Activities of a Bio-Oxidizable Prodrug to Deliver Both ChEs and DYRK1A Inhibitors for AD Therapy

Despite their side effects, cholinesterase (ChE) inhibitors remain the only approved drugs to treat Alzheimer’s disease patients, along with the N-methyl-d-aspartate (NMDA) receptor antagonist memantine. In the last few years, the dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A...

Descripción completa

Detalles Bibliográficos
Autores principales: Barré, Anaïs, Azzouz, Rabah, Gembus, Vincent, Papamicaël, Cyril, Levacher, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479981/
https://www.ncbi.nlm.nih.gov/pubmed/30939771
http://dx.doi.org/10.3390/molecules24071264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479981/
https://www.ncbi.nlm.nih.gov/pubmed/30939771
http://dx.doi.org/10.3390/molecules24071264

Ejemplares similares